# Hyglos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hyglos

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.hyglos.de
- Total disclosed funding: $6M
- Latest round: Series A (Aug 23, 2005)
- Investors on record: 5

## About

Hyglos AG is focused on developing innovative endotoxin detection assays for the pharmaceutical sector, providing sustainable testing alternatives that ensure safety and compliance in product development.Hyglos AG specializes in endotoxin detection solutions, primarily catering to the pharmaceutical industry. The company was acquired by bioMerieux in March 2009 for an undisclosed sum. Founded in Germany, Hyglos operates its headquarters there. It has been involved in two investment deals, with the most recent funding round being a Series A raising EUR 5.000 mn, backed by investors including Bayern Kapital and KfW Banking Group.ENDONEXT™ Solutions provides advanced endotoxin detection assays specifically designed for pharmaceutical applications. Their primary products include recombinant Factor C (rFC) assays, which replace the traditional horseshoe crab blood harvesting method, ensuring high specificity and consistency across various testing scenarios. Additionally, the ENDOZYME® II GO STRIPS offer flexibility in sample usage for laboratories. These products are marketed globally, with significant demand in North America, Europe, and Asia-Pacific, serving both large pharmaceutical companies and smaller biotech firms focused on quality assurance and regulatory standards.ENDONEXT™ Solutions generates revenue through direct sales of its endotoxin detection products and related services to pharmaceuticals. Their B2B model includes sales of assay kits and validation services, supported by partnerships with leading pharmaceutical firms for ongoing technical assistance and routine testing. The revenue structure is designed to meet diverse client needs, including comprehensive packages featuring flagship products like ENDONEXT™ rFC assays and ENDOZYME® II GO STRIPS, which cater to regulatory compliance and product safety testing.Hyglos AG aims to enhance its product line with upcoming innovations in endotoxin detection technologies, though specific launch dates are not detailed. The company plans to expand its market presence in North America and Asia-Pacific by 2025. Following the EUR 5.000 mn Series A funding in March 2009, the company intends to allocate resources towards product development and strengthening its operational capabilities in targeted regions. The acquisition by bioMerieux is expected to further bolster these growth initiatives.

## Funding rounds

- Series A, Aug 23, 2005, $6M — Encavis, Bio Fund Management, KfW Banking Group, Bayern Kapital, Danisco Venture

## Investors

- Encavis — Series A
- Bio Fund Management (https://capitalatlas.ai/funds/bio-fund-management) — Series A
- KfW Banking Group — Series A
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series A
- Danisco Venture (https://capitalatlas.ai/funds/danisco-venture) — Series A